


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Foundation Health LLC d/b/a Fairbanks Memorial Hospital</p> <p>2. 1650 Cowles Street Fairbanks, AK 99701</p>	<p>In accordance with letter dated March 25, 2022; and E-mail dated September 27, 2022 with attachments.</p>	<p>4. Expiration Date: September 30, 2037</p>
	<p>3. License No.: 50-13648-01 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-03509 Reference No.:</p>

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 3.2 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>
--	---	--	--



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:
030-03509

Amendment No. 63

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

9. Authorized use

F. Gadolinium-153

F. Sealed Sources (Eckert & Ziegler Isotope Products/Eckert & Ziegler Nuclitec GmbH/Eckert & Ziegler CESIO, Model NES8412; North American Scientific, Inc., Model MED 3601)

F. 300 millicuries per source and 1.2 curies total

F. For use in attenuation correction of gamma camera imaging systems.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:

030-03509

Amendment No. 63

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities (Imaging Center and the Heart Center) located at 1650 Cowles Street, Fairbanks, Alaska, 99701
11. The Radiation Safety Officer (RSO) for this license is David L. Evans, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists, in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|---|
| Mark Burton, M.D. | 35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction in imaging systems |
| Janice Chen, M.D. | 35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction in imaging systems |
| David L. Evans, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131; parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required |
| Keir Fowler, M.D. | 35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction in imaging systems |
| Richard A. Hattan, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries; Gadolinium-153 for attenuation correction in imaging systems |
| Douglas Herrin, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Joel S. Marquess, M.D. | 35.100; 35.200; oral administration of sodium iodide I-131 |
| Jessica E. Panko, M.D. | 35.100, 35.200; oral administration of sodium iodide I-131 |
| Jordan Ross, M.D. | 35.100, 35.200; oral administration of sodium iodide I-131 |
| Timothy Ryan, M.D. | 35.100; 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:
030-03509

Amendment No. 63

Authorized User (M.D., D.O., etc.)

Claire M. Waite, M.D.

Gregory James Wood, D.O.....

Romel Wrenn, M.D.....


Material and Use

35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

35.100; 35.200

35.100; 35.200

13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 50-13648-01

Docket or Reference No.:
030-03509

Amendment No. 63

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated March 25, 2022 (ML22090A213)
 - B. E-mail dated September 27, 2022 with attachments (ML22270A182)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Latischa M. Hanson

Digitally signed by Latischa M.
Hanson

By: _____

Date: 2022.09.27 16:41:39 -05'00'

Latischa M. Hanson
Region IVDate: September 27, 2022